

Serial No.: Unknown
Docket No. B45082D1

Sub D1
Sub C2
16. A method of treating a patient suffering from or susceptible to Varicella Zoster virus infection as claimed in claim 15, wherein the second Varicella Zoster protein is selected from the group, gpI, gpII, gpIII, gpIV, gpV or IE62 or immunological functional derivative thereof.

17. A method of treating a patient suffering from or susceptible to Varicella Zoster virus infection as claimed in claim 13, additionally comprising an adjuvant.

Sub D1
18. A method of treating a patient suffering from or susceptible to Varicella Zoster virus infection as claimed in claim 17, wherein the adjuvant preferentially induces a TH1 response.

B1
19. A method of treating a patient suffering from or susceptible to Varicella Zoster virus infection as claimed in claim 18, wherein the antigen is presented as an oil in water emulsion together with QS21 and 3D-MPL.

Sub C3
20. A method of producing a pharmaceutical composition comprising a Varicella Zoster virus IE63 protein, nucleic acid or immunologically functional derivative thereof, comprising mixing said protein, nucleic acid or derivative with a pharmaceutically acceptable excipient.

Sub D1
21. A method as claimed in claim 20, wherein the excipient comprises an adjuvant.